Performance of Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients
Performance of Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients
复制标题
DOI：
10.1111/apt.12144
复制
发表时间：
2013-01-01
影响因子：
7.6
通讯作者：
Lin, C. -C.
中科院分区：
文献类型：
--
作者：
Chen, T. -M.;Chang, C. -C.;Lin, C. -C.
研究背景REACH-B [慢性B型肝炎患者肝细胞癌（HCC）风险评估]评分系统用于预测非肝硬化慢性B型肝炎（CH B）患者发生HCC的风险。目的评价REACH-B评分系统对符合2012年亚太肝病研究协会（APASL）抗病毒治疗指南的慢性乙型肝炎患者抗病毒治疗资格的区分能力。方法904例慢性乙型肝炎患者为研究对象。记录患者的年龄、性别、肝功能、HBeAg和HBV DNA水平。结果符合抗病毒治疗条件的患者的最低REACH-B风险评分为HBeAg阳性患者7分，HBeAg阴性患者6分。其中，REACH-B评分增加与HBeAg阳性患者的治疗资格无显著相关性[校正比值比（OR）：1.210，95%置信区间（CI）：0.979 1.494，P=0.078]，如校正性别后的Logistic回归分析所示。在HBeAg阴性患者中，REACH-B评分显著预测治疗合格性（校正OR：1.783，95%CI：1.6071.979，P
Background REACH-B [Risk Estimation for Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B] scoring system was developed to predict the risk of HCC in noncirrhotic chronic hepatitis B (CHB) patients. Aim To evaluate the discriminatory performance of REACH-B scoring system in classifying anti-viral treatment eligibility of CHB patients according to the 2012 Asian Pacific Association for the Study of the Liver (APASL) treatment guideline. Methods A total of 904 noncirrhotic CHB were enrolled. Patients' age, gender, liver biochemistry, HBeAg status and HBV DNA levels were recorded. Results The minimum REACH-B risk score for patients to be eligible for anti-viral treatment was 7 for HBeAg-positive and 6 for HBeAg-negative patients. Among them, increasing REACH-B score was not significantly associated with eligibility for treatment [adjusted odds ratio (OR): 1.210, 95% confidence interval (CI): 0.9791.494, P=0.078] in HBeAg-positive patients, as shown by logistic regression analysis after adjusting for gender. In HBeAg-negative patients, REACH-B score significantly predicted the treatment eligibility (adjusted OR: 1.783, 95% CI: 1.6071.979, P